SARS-CoV-2 vaccination in patients with lymphoid hematologic malignancies
10.3760/cma.j.cn115356-20220609-00168
- VernacularTitle:淋系血液肿瘤患者的新型冠状病毒疫苗接种
- Author:
Yawei JIAO
1
;
Shuting CHEN
;
Haiping DAI
Author Information
1. 苏州大学苏州医学院，苏州 215123
- Keywords:
Coronavirus infections;
Lymphoid hematologic malignancies;
SARS-CoV-2 vaccines
- From:
Journal of Leukemia & Lymphoma
2023;32(4):249-252
- CountryChina
- Language:Chinese
-
Abstract:
Patients with lymphoid hematologic malignancies have a poor prognosis after developing SARS-CoV-2 infection, and their seropositivity rate after SARS-CoV-2 vaccination is lower than that of the healthy population. Since most clinical trials of SARS-CoV-2 vaccines do not include immunodeficient populations, the safety and efficacy of various types of SARS-CoV-2 vaccines for patients with lymphoid hematologic malignancies are unclear. Therefore, physicians should decide whether patients with lymphoid hematologic malignancies receive SARS-CoV-2 vaccination and the timing, type and dose of vaccine after taking into full consideration the patient's immune status, type of treatment and the risk of SARS-CoV-2 infection.
